A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance
Eligible for screening study DCP 001
Completion of Pre-Registration QOLs is required after consent, prior to registration. Please see study documents.